The over-the-counter weight-loss medicine alli now carries stronger kidney warnings. The FDA approved changes to its Drug Facts label after rare reports linked orlistat products to kidney stones and acute kidney injury.
The change does not mean every person taking alli will develop a kidney problem. It adds information needed to recognize higher-risk situations and symptoms that should prompt the medicine to be stopped and a clinician contacted.
The warning applies to 60-milligram alli capsules
The FDA Drug Safety Communication, also preserved at the agency’s original safety-page address, concerns the nonprescription 60-milligram form of orlistat sold as alli. The revised label advises people with a history of kidney disease or kidney stones to ask a health professional before use.
Higher-strength orlistat is available by prescription. The labeling change aligns kidney-risk information across FDA-approved orlistat products, so the same underlying concern is not confined to a single package color or retail aisle.
Orlistat changes fat absorption
Orlistat works in the digestive tract by reducing absorption of some dietary fat. That action can alter how oxalate is absorbed, allowing more oxalate to enter the bloodstream and later the urine. Calcium and oxalate can then form crystals or stones.
FDA cited rare reports of hyperoxaluria, calcium oxalate kidney stones and oxalate nephropathy. In oxalate nephropathy, crystals form in kidney tissue and interfere with filtration. Acute kidney injury means the kidneys suddenly cannot clear waste effectively; severe untreated cases can be fatal.
Symptoms should trigger a stop and a call
The revised label tells consumers to stop taking alli and seek medical guidance for back or groin pain, painful urination, blood in the urine, swelling of the feet or legs, or urinating less often. Those symptoms can have several causes, but they warrant evaluation in someone using orlistat.
Sudden severe pain, inability to urinate, marked swelling or signs of serious illness may require urgent care. A list of medicines, supplements and recent symptoms can help a clinician assess the problem. Continuing the drug while waiting for routine advice may conflict with the label’s stop-use direction.
Kidney history belongs in an over-the-counter decision
Nonprescription status does not make a medicine appropriate for every health history. Prior stones, chronic kidney disease, dehydration risk and other medications can change the balance of benefits and harms. A pharmacist can help screen for concerns before purchase.
People already taking alli should read the current Drug Facts panel rather than relying on an older box or memory of earlier instructions. Existing stock may carry previous labeling while retailers transition packages, but the FDA’s safety advice applies regardless of which carton is on hand.
The label change reflects postmarketing evidence
Rare adverse effects may not become clear until a medicine is used by a much larger and more varied population than participated in preapproval trials. Postmarketing case reports can reveal patterns involving medical histories, hydration, diet or other factors that were uncommon in studies.
FDA said the cases showed evidence of kidney injury associated with oxalate crystals and that a dose-independent risk was biologically plausible. The agency therefore added the warning even though the events remain rare. Labeling is meant to communicate severity as well as frequency.
Side effects can be reported
Patients and health professionals can submit suspected medicine problems through FDA MedWatch. A report does not prove that a drug caused an event, but detailed accounts help regulators monitor whether warnings, dosing directions or other safety actions need to change.
Weight-loss treatment decisions can include nutrition, activity, behavioral support and other medications, depending on medical needs. Anyone who stops alli because of symptoms or poor tolerance can discuss alternatives with a qualified health professional rather than restarting without guidance.
Orlistat also has well-known gastrointestinal effects related to unabsorbed fat, but the kidney warning describes a different system and a different set of symptoms. Familiarity with one side-effect profile should not lead someone to dismiss new urinary pain, swelling or reduced output.
Hydration advice must be individualized when kidney or heart conditions are present. Simply drinking excessive water is not a treatment for suspected acute kidney injury or an obstructing stone. Clinical evaluation may include blood tests, urine tests and imaging to determine what is happening.
Medication reviews should include vitamins, herbal products and other nonprescription drugs. A complete list helps a pharmacist or clinician spot overlapping risks and decide whether alli remains appropriate. The updated label turns prior kidney disease and stones into explicit reasons for a pre-use conversation.
Kidneys regulate fluid, electrolytes and waste removal throughout the body, so acute injury may produce symptoms beyond pain. Fatigue, nausea or confusion can accompany more severe impairment. Those nonspecific changes deserve attention when they appear with swelling or reduced urination during orlistat use. Prompt assessment can prevent a worsening problem from being mistaken for an ordinary medication effect.
This article was produced with the assistance of AI and reviewed by Morning Overview editors prior to publication.
More from Morning Overview
- Scientists spotted a rare tusked whale alive at sea for the first time, then fired a crossbow at it.
- A Colorado wildfire forced level-three ‘leave now’ orders across Ouray County
- A skeleton beneath Petra’s Treasury was found clutching a chalice that resembles the Holy Grail
- 8 SUVs mechanics are quietly steering buyers away from in 2026
